| Patents for A61P 35 - Antineoplastic agents (221,099) |
|---|
| 04/22/2009 | CN100480259C Telomerase inhibitory peptides and uses thereof |
| 04/22/2009 | CN100480250C Bromodihydroartemisinin and preparation method thereof |
| 04/22/2009 | CN100480242C CDK-inhibitory pyrimidines, and production and use thereof as pharmaceutical agents |
| 04/22/2009 | CN100480238C Compound for generating nucleic acid cross-linking action by induction and preparing method and use thereof |
| 04/22/2009 | CN100479930C Biological control of nanoparticles |
| 04/22/2009 | CN100479863C Correlation of cofilin 1 and resistance to anticancer taxane chemotherapy medicine |
| 04/22/2009 | CN100479862C Transporters and drug delivery system by using the same |
| 04/22/2009 | CN100479860C Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and alkylating agents |
| 04/22/2009 | CN100479856C Sustained release pharmaceutical compositions for parenteral administration of hydrophilic compounds |
| 04/22/2009 | CN100479833C Extraction method of polygala refined total saponin |
| 04/22/2009 | CN100479828C Preparing method for substance of poly pentenol capsule |
| 04/22/2009 | CN100479824C Combined therapy against tumors comprising substituted acryloyl distamycin derivatives, taxanes and/or antimetabolites |
| 04/22/2009 | CN100479815C Medicine for treating M2 type acute myelogenous leukemia and preparation method of injection thereof |
| 04/22/2009 | CN100479813C Preparation method of capsule possessing antiinflammation, releaving pain and anticancer function |
| 04/22/2009 | CN100479811C Medicinal composition containing backuchiol for treating female breast cancer |
| 04/22/2009 | CN100479806C Nanostructured liposome vector with highly effective antineoplastic activity |
| 04/22/2009 | CN100479805C Chinese caterpillar fungus injection preparation method |
| 04/21/2009 | US7521532 Comprises nucleotide sequences coding transmembrane protein for diagnosis and treatment immunological and autoimmune diseases |
| 04/21/2009 | US7521478 Antitumor agents; synthetic derivatives equivalent to marine polyketide derived components isolated from bryozoan Myriapora truncata; removing protecting groups from intermediates |
| 04/21/2009 | US7521463 Immunomodulatory compounds |
| 04/21/2009 | US7521457 Pyrimidines as PLK inhibitors |
| 04/21/2009 | US7521454 2-butylamino-8-hydroxy-9-(6-methyl-3-pyridylmethyl)adenine; interferon inducing activity; antiviral, antiallergic agent; immune response modulator; hepatitis B and C, asthma, atopic dermatitis |
| 04/21/2009 | US7521453 e.g. 5-Bromo-2-(3-methylisoxazol-5-ylmethylamino)-4-(5-cyclopropyl- 1H-pyrazol-3-ylamino)pyrimidine; anticarcinogenic, antitumor agents; breast, prostate, colon cancer |
| 04/21/2009 | US7521450 Inhibitors of kinases |
| 04/21/2009 | US7521448 N-substituted benzimidazolyl c-Kit inhibitors |
| 04/21/2009 | US7521436 Modified phosphocalcic compound, injectable composition containing same |
| 04/21/2009 | US7521432 Compositions and methods for identifying agents which regulate chromosomal stability, gene activation and aging |
| 04/21/2009 | US7521419 Peptide-based compounds |
| 04/21/2009 | US7521240 Chromosome-based platforms |
| 04/21/2009 | US7521239 Method for introducing a molecule into the cytosol of a cell in which the cell is contacted with a photosensitising agent, the cell is irradiated with light of a wavelength effective to activate the photosensitising agent and, substantially at the |
| 04/21/2009 | US7521215 Polynucleotides, expression vectors, and host cells for culturing truncated tryptophanyl-tRNA synthetase polypeptides having chemokine activity; bioassay; drug screening; antitumor agents, antimetastasis agents |
| 04/21/2009 | US7521212 Method for producing oligopolysaccharides |
| 04/21/2009 | US7521206 Tumor necrosis factor (TNF); immunotherapy or diagnosis of TNF-related diseases such as cancer; nucleic acids, host cells, vectors |
| 04/21/2009 | US7521175 Mutations in the Bcr-Abl tyrosine kinase associated with resistance to STI-571 |
| 04/21/2009 | US7521071 Formulation of oral compositions comprising arsenic trioxide and methods of use thereof |
| 04/21/2009 | US7521068 For pulmonary and nasal drug administration |
| 04/21/2009 | US7521066 Administering non-gas containing nanoparticles comprising a mixture of select lipids capable of being internalized within a targeted tissue or cell sufficient to achieve a desired effect and anticancer agent |
| 04/21/2009 | US7521065 Compositions for the treatment and prevention of cancer |
| 04/21/2009 | US7521054 Reduction of the nonspecific animal toxicity of immunotoxins by mutating the framework regions of the Fv to lower the isoelectric point |
| 04/21/2009 | US7521053 Angiopoietin-2 specific binding agents |
| 04/21/2009 | US7521052 Administering an effective amount of an anti-IL-6 receptor antibody (anti-IL-6R antibody) and an effective amount of methotrexate (MTX) for therapy of rheumatoid arthritis |
| 04/21/2009 | US7521043 Gene therapy for tumors using minus-strand RNA viral vectors encoding immunostimulatory cytokines |
| 04/21/2009 | CA2182949C Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis |
| 04/21/2009 | CA2157855C Benzoylguanidines substituted by heterocyclic n-oxide, process for their preparation, their use as a medicament or diagnostic agent, medicament containing them and intermediate products for their preparation |
| 04/19/2009 | CA2607149A1 Predicting responsiveness to cancer therapeutics |
| 04/16/2009 | WO2009049132A1 Quinoline derivatives for modulating dna methylation |
| 04/16/2009 | WO2009049111A1 2-((r)-2-methylpyrrolidin-2-yl)-1h-benzimidazole-4-carboxamide crystalline form 1 |
| 04/16/2009 | WO2009049109A1 2-((r)-2-methylpyrrolidin-2-yl)-1h-benzimidazole-4-carboxamide crystalline form 2 |
| 04/16/2009 | WO2009048760A2 Biphenyl inhibitors of carbonyl reductase |
| 04/16/2009 | WO2009048474A1 2,7,9-substituted purinone derivatives for immunosuppression |
| 04/16/2009 | WO2009048123A1 Bis(trimethylsilyl)phenyl compound or salt thereof, and use thereof |
| 04/16/2009 | WO2009047752A1 Breast cancer therapy |
| 04/16/2009 | WO2009047563A1 Pyrrolo [2, 3 -d] pyrimidin derivatives as protein kinase b inhibitors |
| 04/16/2009 | WO2009047522A1 Bicyclic heterocyclic compounds as protein tyrosine kinase inhibitors |
| 04/16/2009 | WO2009047513A2 Antagonists of kisspeptin and uses thereof |
| 04/16/2009 | WO2009047506A1 Bicyclic heterocyclic compounds as protein tyrosine kinase inhibitors |
| 04/16/2009 | WO2009047323A2 Isoxazole compound for the treatment of cancer |
| 04/16/2009 | WO2009047298A2 Dimers of harmol or of its derivatives and uses thereof |
| 04/16/2009 | WO2009047291A2 Use of quaternary pyridinium salts for inhibiting cancer metastases |
| 04/16/2009 | WO2009047216A2 Use of indolocarbazole imides as protein kinase inhibitors for the treatment of hematologic and solid tumors |
| 04/16/2009 | WO2009047161A1 Chiral cis-imidazolines |
| 04/16/2009 | WO2009047006A2 Amphoteric liposomes comprising neutral lipids |
| 04/16/2009 | WO2009046881A1 Use of a peptide combination including c-peptide, as a therapeutic agent |
| 04/16/2009 | WO2009046880A2 Use of a peptide as a therapeutic agent |
| 04/16/2009 | WO2009046879A2 Use of the combination of npy and nociceptin as a therapeutic agent |
| 04/16/2009 | WO2009046878A1 Tnf inhibitory peptide and cgrp as therapeutic agents |
| 04/16/2009 | WO2009046877A2 Use of a histrelin and leuprolide as therapeutic agents |
| 04/16/2009 | WO2009046875A2 Combination of splenopentin and thymopentin and the use thereof in medicine |
| 04/16/2009 | WO2009046874A1 Therapeutic combination of trh-potentiating peptide and stresscopin |
| 04/16/2009 | WO2009046873A1 Combined use of vasonatrin and gastrin-i as a therapeutic agent |
| 04/16/2009 | WO2009046872A2 Use of a peptide as a therapeutic agent |
| 04/16/2009 | WO2009046868A1 Use of a peptide as a therapeutic agent |
| 04/16/2009 | WO2009046867A2 Caerulein alone or in combination with acth (3-24 ) as therapeutic agent |
| 04/16/2009 | WO2009046866A2 Trap-14 as a therapeutic agent |
| 04/16/2009 | WO2009046865A2 Cholecystokinin-33 alone or in combination with trap-14 as therapeutic agent |
| 04/16/2009 | WO2009046864A2 Use of the human pancreatic polypeptide as a therapeutic agent |
| 04/16/2009 | WO2009046863A2 Use of thymosin alpha 1 peptide or the combination with the human pancreatic polypeptide as a therapeutic agent |
| 04/16/2009 | WO2009046862A1 Use of physalemin as a therapeutic agent |
| 04/16/2009 | WO2009046861A1 Use of cnp-22, alone1 or in combination with physalemin, as a therapeutic agent |
| 04/16/2009 | WO2009046860A2 Use of dago as a therapeutic agent |
| 04/16/2009 | WO2009046859A2 Use of af12198 and dago as therapeutic agents |
| 04/16/2009 | WO2009046858A2 Therapeutic uses of kisspeptin 13 and compositions thereof |
| 04/16/2009 | WO2009046857A1 Use of a peptide as a therapeutic agent |
| 04/16/2009 | WO2009046856A2 Use of serorphin as a therapeutic agent |
| 04/16/2009 | WO2009046853A1 Use of intermedin 47 peptide as a therapeutic agent |
| 04/16/2009 | WO2009046852A1 Therapeutic uses of intermedin 47 and 53 peptides |
| 04/16/2009 | WO2009046851A1 Cgrp as a therapeutic agent |
| 04/16/2009 | WO2009046850A1 Cgrp as a therapeutic agent |
| 04/16/2009 | WO2009046849A1 Use of the peptide cecropin a as a therapeutic agent |
| 04/16/2009 | WO2009046848A1 Use of the peptide thymosin beta 4 alone or in combination with cecropin a as a therapeutic agent |
| 04/16/2009 | WO2009046847A2 Use of peptide ll-37 as a therapeutic agent |
| 04/16/2009 | WO2009046846A2 Use of il-1 receptor peptide, alone or in combination with peptide ll-37, as a therapeutic agent |
| 04/16/2009 | WO2009046845A2 Use of a lactoferrin partial peptide peptide as a therapeutic agent |
| 04/16/2009 | WO2009046844A1 Therapeutic uses of peptide tdvngdgrhdl |
| 04/16/2009 | WO2009046843A1 Therapeutic uses of peptides kvlpvpq and/or tdvngdgrhdl |
| 04/16/2009 | WO2009046842A2 Thiazol derivatives for treating cancer |
| 04/16/2009 | WO2009046841A2 Piperidine and piperazine derivatives for treating tumours |
| 04/16/2009 | WO2009046835A1 Use of goserelin and amylin as therapeutic agents |
| 04/16/2009 | WO2009046834A2 Use of t140 and optionally retrocyclin-1 as therapeutic agents for the treatment of m. tuberculosis infections |
| 04/16/2009 | WO2009046833A1 Use of a peptide as a therapeutic agent |